Answers are grounded in this paper and cite their sources.
As for any novel nanomaterial, the development of applications and industrial adoption of graphene-based materials will be subject to the confirmation of their safety profile and risk assessment. The analysis performed here maps the current knowledge of the safety of graphene-based materials as extracted by a literature mapping exercise of studies investigating these materials in preclinical animal models. We attempt to identify gaps for future studies and elucidate the critically important structure-function correlations between reported biological effects and graphene-based material physicochemical characteristics.
No takes yet. Share an insight, caveat, or question.
Bussy et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: